Repligen | RGEN - Current Liabilities


Repligen reported $125.69M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Agilent USD 2.29B 20M Jun/2026
Align Technology USD 1.91B 4.9M Sep/2026
Bio Techne USD 361.27M 197.57M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Bruker USD 1.17B 32.6M Sep/2026
Charles River Laboratories USD 1.09B 45.49M Sep/2026
Danaher USD 9.05B 945M Sep/2026
Dentsply International USD 1.22B 32M Sep/2026
General Electric Aerospace USD 42.4B 1.96B Sep/2026
Henry Schein USD 3.6B 110M Sep/2026
Illumina USD 1.16B 422M Sep/2026
IQVIA Holdings USD 7.78B 1.04B Sep/2026
Mettler Toledo International USD 1.25B 49.81M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
OraSure Technologies USD 25.12M 18.96M Jun/2026
Pacific Biosciences Of California USD 66.59M 2.21M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Repligen USD 125.69M 6.97M Sep/2026
Revvity USD 701.48M 574.88M Sep/2026
Standard Biotools USD 51.02M 5.78M Sep/2026
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Waters USD 2.4B 126M Jun/2026
West Pharmaceutical Services USD 644.3M 3.8M Sep/2026